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AbstrACt
Introduction The The BIOlogical Dose OPTimisation 
(BIODOPT) trial is a pragmatic, multicentre, randomised 
controlled, open-label, parallel-group, equivalence study 
designed to evaluate tapering of biological disease-
modifying antirheumatic drugs (bDMARDs) in patients with 
rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial 
spondyloarthritis (axSpA) in sustained clinical remission 
or low disease activity (LDA). Traditionally, these patients 
maintain standard dosage of bDMARD lifelong; however, 
recent studies indicate that a significant proportion of 
patients in sustained remission or LDA can taper their 
bDMARD and maintain stable disease activity. Thus, this 
trial aims to evaluate whether a disease activity-guided 
tapering strategy for bDMARDs will enable a significant 
dosage reduction while maintaining disease activity 
compared with usual care. From the individual patient’s 
standpoint as well as from a societal perspective, it would 
be advantageous if bDMARDs could be reduced or even 
discontinued while maintaining disease activity.
Methods and analysis A total of 180 patients with 
RA, PsA or axSpA treated with bDMARDs and in clinical 
remission/LDA during the past 12 months will be enrolled 
from four centres in Denmark. Patients will be randomised 
in a ratio of 2:1 to either disease activity-guided tapering 
of bDMARDs (intervention group) or continuation of 
bDMARDs as usual care (control group). The primary 
objective is the difference between the two groups in the 
proportion of patients who have reduced their inclusion 
dosage of bDMARDs to 50% or less while maintaining 
stable disease activity at 18 months follow-up.
Ethics and dissemination The study is approved by 
the ethics committee of Northern Jutland, Denmark (N-
20170073) and by the Danish Medicine Agency. Patient 
research partner KHH contributed to refinement of the 
protocol and approved the final manuscript. Results will 
be disseminated through publication in international peer-
reviewed journals.
trial registration number 2017-001970-41; Pre-results.
IntroduCtIon
Over the last decades, the introduction of 
biological disease-modifying antirheumatic 
drugs (bDMARDs) such as tumour necrosis 
factor (TNF)-α blockers, interleukin-6 
receptor blockers and costimulation blockers 
together with the treat to target paradigm 
have significantly improved treatment options 
for patients with inflammatory arthritis 
such as rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and axial spondyloarthritis 
(axSpA).1–9 To date, the treatment strategy 
has focused on initial efficacy aiming for low 
disease activity (LDA) or even remission. 
strengths and limitations of this study
 ► Randomised controlled, equivalence trial evaluat-
ing tapering of biological disease-modifying anti 
rheumatic drugs (bDMARDs) in relation to disease 
activity among patients with rheumatoid arthritis, 
psoriatic arthritis and axial spondyloarthritis.
 ► Involvement of a patient research partner.
 ► Dosage reduction algorithm is feasible to implement 
as a pragmatic (‘real-world’) setting.
 ► Inability to design and perform the study as a dou-
ble-blinded trial.
 ► Heterogeneity across the study population regarding 
diagnosis and bDMARDs may limit analyses.
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Thus, standard dosage is often continued lifelong to 
maintain disease control despite limited evidence that 
it is necessary. Dosage reduction or discontinuation of 
bDMARDs is an important topic in light of the increasing 
number of patients who reach remission or LDA and the 
risk of unnecessary adverse events due to overtreatment, 
for example, infections. To our knowledge, no treatment 
guidelines states precisely how tapering of bDMARDs in 
patients with RA, PsA or axSpA in sustained remission or 
LDA should be done, that is, at which frequency the dose 
should be reduced or the dosing interval prolonged.10–15
Previous literature show that discontinuation of a 
bDMARD without prior dosage reduction leads to flare 
in up to 40%–75% of patients with RA,16 17 76%–100% 
of patients with axSpA18 and 55%–100% of patients with 
PsA.19–21 Thus, abrupt discontinuation of bDMARDs 
results in flare in a significant proportion of patients. 
Another approach is to use a tapering algorithm to 
gradually reduce dosage or increase the dosage interval 
of bDMARDs to identify patients who can taper or even 
discontinue their bDMARD. Recent studies indicate 
that a significant proportion of patients can taper their 
bDMARDs and still maintain remission or LDA.16–18 22–29 
van Herwaarden et al showed that a disease activity-guided 
tapering strategy of adalimumab or etanercept for patients 
with RA was non-inferior to usual care when considering 
major flaring.30 In the tapering group 18 months from 
baseline, adalimumab or etanercept were successfully 
discontinued in 20% of the patients, and the dosage 
interval was successfully increased in 43%; yet, no dosage 
reduction was possible for 37%. In the extension phase, 
safety and efficacy of the disease activity-guided tapering 
strategy of adalimumab or etanercept was maintained at 3 
years from baseline.31 Fautrel et al did not disprove the null 
hypothesis of non-inferiority in the STRASS study due to 
insufficient recruitment; however, in the tapering group 
18 months from baseline adalimumab or etanercept were 
successfully stopped in 39.1% and successfully tapered 
in 35.9% while standard dose had to be maintained in 
20.3%.32 A non-inferiority trial including ankylosing 
spondylitis (AS) in remission on adalimumab, etanercept, 
infliximab or golimumab, which was stopped prema-
turely due to funding problems, found that prolonging 
the dosing interval of anti-TNF by 25% was non-inferior 
to full-dosage anti-TNF as LDA was maintained in 81.3% 
of patients in the tapered group and 83.8% of patient in 
the full-dose group.22 In addition, Cantini et al showed 
in a randomised controlled trial (RCT) that 90.4% of 
patients with AS on full-dose etanercept and 86.3% of 
patients with AS on half-dose etanercept was still in remis-
sion after a mean follow-up of 21–22 months.33 Further-
more, prospective observational studies in AS and axSpA 
have proven that a large proportion of patient maintain 
remission/LDA after tapering of bDMARDs.34 35 To our 
knowledge, there are currently neither equivalence nor 
non-inferiority trials exploring tapering of bDMARDs 
in patients with PsA using a disease activity-guided algo-
rithm. However, a prospective observation study has 
shown that 72% of patients treated with 25 mg etanercept 
maintained remission 1 year after a progressive dosage 
reduction with 21% receiving weekly dosage and 51% 
receiving a dosage every-other-week.27 Additionally, in a 
case–control study including patients with PsA and RA 
in remission on adalimumab, the proportion of patients 
maintaining remission was statistically significant higher 
among patients with PsA (88.6%) than RA (17.6%) after 
50% dosage reduction.28
The BIOlogical Dose OPTimisation (BIODOPT) trial is 
a pragmatic, multicentre, randomised controlled, open-
label, parallel-group, equivalence study as a small dosage 
reduction in bDMARDs is allowed in the control group 
as usual practice in Denmark; hence, the trial will assess 
the implementation of a disease activity-guided tapering 
algorithm for bDMARD compared with usual care. Thus, 
the aim of this study is to evaluate whether a disease activ-
ity-guided tapering strategy for bDMARDs will enable a 
significant dosage reduction while maintaining disease 
activity assessed 18 months from baseline compared with 
usual care. The secondary aims are to identify possible 
prognostic factors for flare as well as predicting patients 
who are likely successful dosage reduction candidates. 
Additionally, we assess if decreased use of bDMARDs 
in the intervention group will result in a lower rate of 
adverse events; for example, infections.
MEthods And AnAlysIs
Patient and public involvement
Collaboration between patients and health professionals 
during initiation and conduct of research trials provides 
both parties with shared knowledge.36 Two patient 
research partners were included in the initial develop-
ment of this protocol after the research question was 
developed. One of the patient partners has provided 
additional advice incl. assessment of the burden of the 
intervention; thereby, contributing to and approving the 
final protocol manuscript and final patient trial informa-
tion. No patient partners is involved in recruitment or 
conduct of the trial. Trial results will be disseminated to 
the participants from research personnel.
study design
The trial is a pragmatic, multicentre, randomised 
controlled, open-label, parallel-group, equivalence trial 
of 18 months duration conducted at four locations in 
Denmark. After the intervention period, a follow-up 
examination will be performed at 24 and 60 months from 
baseline as seen in figure 1A and figure 1B.
Participants and settings
Patients diagnosed with RA, PsA (peripheral) or axSpA 
(incl. axial PsA) in sustained remission or LDA on 
bDMARDs are considered for inclusion and will receive 
written and oral information about the trial by the investi-
gator. Patients will be included in the trial if they fulfil the 
eligibility criteria and have signed the informed consent 
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form. Patients are recruited at routine visits at four 
rheumatology outpatient clinics in Denmark: Aalborg 
University Hospital, Aarhus University Hospital, Odense 
University Hospital and The Hospital of South West 
Jutland, Esbjerg.
Inclusion criteria
 ► ≥ 18 years of age.
 ► RA diagnosed by the 2010 American College of Rheu-
matology (ACR)/European League Against Rheu-
matism (EULAR) criteria,37 and/or 1987 ACR RA 
criteria,38 axSpA diagnosed by the 1984 modified New 
York criteria for ankylosing spondylitis,39 and/or 2009 
Assessment of SpondyloArthritis (ASAS) classification 
of axSpA,40 and/or PsA according to CLASsification 
criteria for Psoriatic ARthritis (CASPAR)41 and/or 
Moll and Wright criteria.42
 ► Treatment with abatacept, adalimumab, certolizumab 
pegol, etanercept, golimumab, infliximab or tocili-
zumab incl. biosimilars in stable dosage during the 
last 12 months.
 ► Sustained remission or LDA (as defined by the disease 
activity criteria for enrolment below) during the last 
12 months measured by ≥2 registrations in the Danish 
Rheumatology Database (DANBIO).
 ► For female participants with childbearing potential: a 
negative pregnancy test at baseline and practising safe 
birth control.
Exclusion criteria
 ► Current oral prednisolone treatment.
 ► Intra-articular or parenteral administration of corti-
costeroids or a short course of oral prednisolone 
within the last year.
 ► Dosage reduction of bDMARDs is not suitably judged 
by medical expert.
 ► Female participants who are pregnant or breast-
feeding or considering becoming pregnant.
 ► Participants with a history of psychiatric or psycholog-
ical conditions that, in the opinion of the investigator, 
will affect the ability to participate in the trial.
 ► Addictive or previous addictive behaviour.
Disease activity criteria for enrolment
The disease activity criteria for inclusion is: (1) RA: Disease 
Activity Score28crp (DAS28crp)<3.243 and no swollen 
joints assessed by 46 joint count, (2) PsA: Disease Activity 
in PSoriatic Arthritis (DAPSA)≤1444 and no swollen joints 
assessed by 66/68 joint count and (3) axSpA: Ankylosing 
Spondylitis Disease Activity Score (ASDAS)<2.145 and 
if additional peripheral involvement no swollen joints 
assessed by 66/68 joint count.
Flare criteria
We define that an arthritis flare in this study requires 
exclusion of other reasons for flare, for example, 
infection, lack of adherence or short pause in 
bDMARD therapy, for example, due to surgery. The 
flare criteria are: (1) RA and PsA: ∆DAS28crp>1.2 
or ∆DAS28crp>0.6 and current DAS28crp≥3.2 and 
(2) axSpA: inflammatory back pain (assessed by the 
physician) and ∆ASDAS ≥0.9 and/or ≥1 swollen joint 
assessed by 66/68 joint count.
Patients who flare due to dosage reduction will go 
one step back in the algorithm, that is, to the dosage 
of bDMARD before the arthritis flared. Intra-articular 
steroid and/or a short course of Non-Steroidal Anti-In-
flammatory Drugs (NSAID) (max 14 days) are allowed 
to treat a flare. Patients with sustained flare and no 
effect of dosage increase are treated in accordance with 
the national guidelines, for example, switch to another 
bDMARD.
If a patient has symptoms of psoriasis, uveitis or inflam-
matory bowel disease (IBD) flare during tapering, the 
relevant department is contacted for dialogue and expert 
opinion in particular indication for bDMARD dosage 
escalation.
Interventions
Participants are randomised in ratio 2:1 to either the 
intervention group or the control group. Disease activity 
is monitored at the rheumatology outpatient clinics every 
4 months during the first year; thereafter, the primary 
endpoint assessment is scheduled at 18 months from 
baseline. A long-term follow-up visit will be performed at 
24 and 60 months from baseline. During the BIODOPT 
trial, disease activity incl. flare is assessed by DAS28crp46 
Figure 1 (A,B) An overview of the BIODOPT trial incl. 
intervention groups and subsequent follow-up visits (after 
primary endpoint). ASDAS, Ankylosing Spondylitis Disease 
Activity Score; bDMARDs, biological disease-modifying 
antirheumatic drugs.
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for patients with RA and PsA and by ASDAS47 for patients 
with axSpA.
At baseline, patients in both trial groups are educated 
about symptoms of flare by research personnel, for 
example, increasing peripheral joint pain and/or joint 
swelling and/or increasing inflammatory back pain. If 
such symptoms occur, the patients are advised to contact 
the rheumatology outpatient clinic for a consult within 7 
days.
Intervention (BIODOPT) group
In the intervention group, dosage reduction of bDMARDs 
is done stepwise throughout the first year according to a 
disease activity-guided algorithm until flare or discontinu-
ation. Thus, bDMARD can be withdrawn after 12 months 
if disease activity is maintained.
If the patient has symptoms of flare due to tapering 
but the arthritis is in remission assessed by the physician, 
the patient is advised to continue tapering according to 
the BIODOPT algorithm but may remain at the current 
dosage (or even go back one step in the algorithm).
Patients on reduced dosage of bDMARDs at baseline 
(relative to standard dosage) are reduced to the nearest 
level in the algorithm at the first dosage reduction.
Comparator (control) group
In the control group, bDMARDs are continued as usual 
care. Thus, standard dosage of bDMARDs is continued 
throughout the study period for most patients, but 
according to usual care practice in Denmark, the patient 
and physician can decide to taper bDMARDs by a small 
increase in the dosage interval.
the bIodoPt algorithm
In the intervention group, dosage of bDMARDs (incl. 
biosimilars) is reduced gradually over 12 months by 
prolonging the dosage intervals. The algorithm is used to 
minimise the risk of flare due to rapid dosage reduction. 
As long as the patients are in remission, they continue 
to adhere to the dosage reduction algorithm. Dosage of 
bDMARDs (excluding infliximab) is reduced with approx-
imately 25% every 4 months, see figure 2A. As infliximab 
is administered at longer dosage intervals, the algorithm 
is different; hence, the dosage interval is prolonged with 
2 weeks at each infusion, see figure 2B.
drug accountability
BATCH numbers of the study drug will be registered 
by research personnel when the intravenous bDMARD 
is administered or when the subcutaneous bDMARD is 
handed out to the patient in the outpatient clinic. At 
each trial visit, drug accountability incl. compliance to the 
intervention group is recorded. The participant is given a 
patient journal at each trial visit to keep track of any study 
drug change, for example, pause due to infection.
Baseline concomitant synthetic DMARD and/or 
NSAID dose are maintained throughout the study period; 
however, dosage can be reduced or discontinued if the 
patient experiences substantial side effects.
demographic data and medical history
At baseline, the patients’ medical history incl. demo-
graphic data are obtained through patient interviews 
and the patients’ medical records. Table 1 illustrates a 
schematic overview of the scheduled assessments incl. 
the demographic and medical history with subsequent 
outcomes collected during the BIODOPT trial.
Patient reported outcome measures
As is usual practice in Denmark, patient reported outcome 
measures are collected electronically through the touch-
screen in the outpatient clinic as shown in table 1. Addi-
tionally, the Short Form Health Survey 36 (SF-36)48 is 
assessed in paper form at each trial visit in order to assess 
as many aspects as possible of the patient’s experience 
during tapering of bDMARDs.
Clinical and laboratory assessment
The clinical and laboratory assessments performed 
during the BIODOPT trial are shown in table 1.
Imaging
Radiological examinations including MRI are conducted 
in accordance with national guidelines for treatment 
change and not as part of this trial.
randomisation
All patients will be randomly allocated in permuted 
blocks of three to six by a computer-generated rando-
misation sequence with an allocation ratio of 2:1, strat-
ified by trial site (Aalborg, Aarhus, Odense or Esbjerg), 
diagnosis (ie, RA, axSpA or PsA) and repeated bDMARD 
failure (currently on bDMARD number 1–2 or higher). 
SAS PROC PLAN was used to generate the 24 mutu-
ally independent randomisation schedules (4 centres×3 
diagnoses×2 bDMARD ‘stages’); SAS statistical software 
V.9.4. The randomisation sequence was performed by the 
senior biostatistician with no clinical involvement in the 
trial (RC).
Figure 2 The dosage reduction algorithm for (A) 
all bDMARD excluding infliximab and (B) infliximab. 
bDMARD, biological disease-modifying antirheumatic drugs. 









pen: first published as 10.1136/bm




5Uhrenholt L, et al. BMJ Open 2019;9:e028517. doi:10.1136/bmjopen-2018-028517
Open access






Month 0 4 8 12 18 24 60
Demographic data X
Medical history X
Patient reported outcome measures
  Visual Analogue Scale (VAS) pain (0–100)64 65* X X X X X X X
  VAS global (0–100)* X X X X X X X
  VAS fatigue (0–100)* X X X X X X X
  Health Assessment Questionnaire Disability Index 
(0–3)66*
X X X X X X X
  Short Form Health Survey 36 X X X X X X X
  Bath Ankylosing Spondylitis Disease Activity Index 
(0–100)67*† 
X X X X X X X
  Bath Ankylosing Spondylitis Functional Index (0–100)68*† X X X X X X X
Clinical assessments
  Height (cm) and weight (kg) X
  Blood pressure (mm Hg) and pulse (beats/minute) X
  Swollen and tender joint count (number)‡ X X X X X X X
  Bath Ankylosing Spondylitis Metrology Index (0–100)69† X X X X X X X
  Spondyloarthritis Research Consortium Canada 
Enthesitis score70§
X X X X X X X
  Dactylitis (0–20)§ X X X X X X X
  Psoriasis Area Severity Index score71§ X X X X X X X
  Modified Nail Psoriasis Severity Index score72§ X X X X X X X
  VAS physician (0–100)64 X X X X X X X
  Adverse events incl. infections X X X X X X X
Composite scores
  Disease Activity Score28crp¶ X X X X X X X
  Ankylosing Spondylitis Disease Activity Score‡ X X X X X X X
Laboratory assessments
  Routine blood tests** X X X X X X X
  Baseline blood tests†† X
  ACPA, IgM-RF, ANA X
  HLA-B27‡ X
  Biomarker collection for biobank X X X X X X X
  Blood human chorion gonadotropin (B-hCG)‡‡ X
Imaging
  X-ray hands and feet¶ X X
  X-ray SI joints‡ X X
*Registered electronically through the touch screen in the outpatient clinic.
†Assessed for patients with axSpA.
‡46 joint count for patients with RA and 66/68 joint count for patients with PsA or axSpA.
§Assessed for patients with PsA and axSpA.
¶Assessed for patients with RA and PsA.
**C-reactive protein, haemoglobin, differentiated white cell count, platelets, creatinine, alanine transaminase and alkaline phosphatase.
††Uric acid, thyroid-stimulating hormone, vitamin D status.
‡‡Performed in women of childbearing potential at baseline.
ACPA, anti-cyclic citrullinated peptide; ANA, antinuclear antibody; axSpA, axial spondyloarthritis; HLA, human leukocyte antigen; IgM-RF, 
immunoglobulin M-rheumatoid factor; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SI, sacroiliac joint.
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Allocation concealment and implementation
The allocation sequences are concealed in a password-pro-
tected computer file only accessible by the senior biostat-
istician (RC) and an independent data manager. The 
independent data manager entered the randomisation 
sequence in the electronic case report form (e-CRF) 
in REDCap. When enrolled, the participants will be 
randomised and given their randomisation group when 
the physician ‘clicks’ on the ‘randomisation button’ in 
the e-CRF in REDCap. The assigned intervention will 
then be visible on the screen. Thus, the patients are given 
randomisation numbers independent of the trial site with 
concealed group allocation.
The interventions in this trial are not blinded.
Primary outcome
The primary objective is to evaluate whether a disease 
activity-guided tapering strategy for bDMARDs will enable 
a significant dosage reduction while maintaining disease 
activity assessed 18 months from baseline compared with 
usual care. Thus, there are two primary efficacy endpoints:
1A Superiority: The proportion of patients who at 18 
months are reduced to 50% or less of their inclusion dose 
of bDMARD.
1B Equivalence: Disease activity assessed 18 months 
from baseline.
The primary objective is met if a statistically significant 
reduction in biologics is demonstrated while maintaining 
an equivalent disease state.
secondary outcomes
Secondary outcomes are listed in table 1 and include 
identifying possible prognostic factors for flare as well 
as predictors for candidates likely for successful dosage 
reduction of bDMARDs. Additionally, adverse event rates 
are examined in both groups to evaluate if decreased use 
of bDMARDs in the intervention group will result in a 
lower rate of adverse events, for example, infections.
tertiary (exploratory secondary) outcomes
Tertiary outcomes are to explore, if blood levels of cyto-
kines, drug-level, antidrug–antibodies or changes in 
these variables from baseline are a predictor for flare or 
successful dosage reduction.
statistical methods
Sample size and power considerations
The sample size calculation is done in accordance with 
the DELTA2 guideline for reporting sample size calcula-
tions in RCTs.49
1A: We assume that 30% of the patients allocated to 
the intervention group and 5% of patients allocated to 
the control group will meet primary endpoint 1A. This 
assumption is inspired from the DRESS-RA trial, which it 
is one of the very few randomised, non-inferiority/equiv-
alence trials exploring a disease activity-guided tapering 
algorithm among patients with inflammatory arthritis.30 
No randomised, non-inferiority/equivalence study 
exploring a disease activity-guided tapering algorithm was 
to our knowledge published in PsA or axSpA when the 
sample size calculation was performed; however, based on 
the available literature, it seems reasonable to assume that 
the percentage of patients with PsA or axSpA meeting 
primary endpoint 1A will be the same as for RA.22 27 28 33 
Thus, the sample size calculation was not done for each 
disease separately.
For a comparison of two independent binomial propor-
tions using Pearson’s χ2 statistic with a χ2 approximation 
with a two-sided significance level of 0.05, a total sample 
size of 180 assuming an allocation ratio of 2:1 has a 
very high statistical power of 0.992 (99%) if the propor-
tion of patients significantly reducing their bDMARDs 
(≥50% reduction) are 30% and 5%, respectively.
1B: For the between-group comparison, members of the 
BIODOPT trial group (SK, AS, EMH and LU) decided 
a predefined margin of equivalence at ±0.5 DAS28crp 
points for patients with RA or PsA and ±0.5 ASDAS points 
for patients with axSpA. This margin was determined 
based on ‘less than half of the effect’ that would be consid-
ered a clinically relevant reduction in DAS28crp level 
(∆DAS28crp>1.2) or ASDAS level (∆ASDAS >1.1) corre-
sponding to a clinically unimportant change in arthritis 
disease activity. In a two one-sided test analysis for additive 
equivalence of two-sample normal means with bounds±0.5 
for the mean difference and a significance level of 0.05, 
assuming a mean difference of 0 and a common SD of 
1.0, a total sample size of 180 participants assuming an 
allocation ratio of 2:1 yields a sufficient statistical power 
of 0.868 (87%). The sample size was determined from 
the power of the coprimary endpoint with the least statis-
tical power, that is, primary endpoint 1B which is why the 
power for superiority of 0.992 appears extremely high. 
Thus, inclusion of 180 patients (randomised 2:1) in total 
during an inclusion period of 1 year is planned.
Drop-out considerations is based on primary endpoint 
1B, as this is the endpoint with the lowest power (0.868). 
In a two one-sided test analysis for additive equivalence 
of two-sample normal means with bounds −0.5 and 0.5 
for the mean difference and a significance level of 0.05, 
assuming a mean difference of 0 and a common SD of 1, a 
total sample size of 156 assuming an allocation ratio of 2:1 
is required to obtain a power of at least 0.8 (power=0.802). 
Thus, 24 drop-outs (180–156) are allowed corresponding 
to 13%.
Statistical analysis
All descriptive statistics and tests will be reported in accor-
dance to the recommendations of the Enhancing the 
QUAlity and Transparency Of Health Research network50 
including the Consolidated Standards of Reporting 
Trials statements.51 52 Thus, all data analyses will be carried 
out according to a pre-established statistical analysis plan. 
The analyses for the primary and secondary endpoints 
will be conducted according to the ITT principle; that is, 
based on the full analysis set (all randomised individuals 
independent of protocol violations) with outcome data 
available (as observed).53 For the equivalence analyses 
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(ie, according to disease activity), imputations will not be 
used to replace missing data in the primary analyses, but 
will be included in a sensitivity analysis to assess the effect 
of missing data. Thus, ITT analyses with replacement of 
missing data as well as analysis on ‘per protocol’ individ-
uals will only be performed to explore the robustness of 
our findings.
To evaluate the longitudinal effects of the intervention, 
all continuous outcome variables (eg, disease activity 
(1B)) will be analysed using a multilevel repeated-mea-
sures linear mixed effects model, with participant as 
random effect factor based on a restricted maximum like-
lihood model. The model will include group (ie, inter-
vention vs usual care), diagnosis, bDMARD failure history, 
centre status and time point (4, 8 and 12 months from 
baseline) as fixed effects, with the baseline value of the 
relevant variable (eg, disease activity (1B)) as a covariate. 
A two-sided 95%  CI for the difference in disease activity 
at 18 months follow-up between groups will be derived 
from the repeated-measures mixed linear model and 
equivalence will be declared if the 95% CI of disease 
activity level is completely within the prespecified equiva-
lence range (−0.5 units to +0.5 units). Dichotomous end 
points (eg, number of participants who achieve a signifi-
cant reduction in bDMARDs (≥50%) while assessed after 
18 months) will be analysed with the use of simple logistic 
regression with the same fixed effects and covariates as 
the respective analysis of covariance; unlike the contin-
uous outcome proportions responding will only be anal-
ysed following 18 months.
For the superiority tests (eg, composite primary 
endpoint (1A)), we set the statistical significance at 
the conventional level of 0.05 (p<0.05). Results will be 
expressed as estimates of the differences between groups, 
with 95% CIs to represent precision of the estimates. 
Multiplicity considerations clearly play a central role in 
the assessment of efficacy evidence in the presence of 
competing clinical objectives (eg, composite primary 
endpoints).54 In the BIODOPT trial, we apply a hierar-
chical primary endpoint in order to adjust for the fact that 
the more tests you do, the more likely it is that a compar-
ison appear as falsely significant. In the BIODOPT trial, 
the primary superiority objective is to reduce the use of 
bDMARDs in patients with inflammatory arthritis (by at 
least 50%) compared with the control group, while still 
maintaining a similar disease control (equivalence). 
Because this trial will have two potential ‘efficacy claims’, 
a hierarchical test approach will be used to preserve the 
overall type I error rate at a two-sided alpha level of 0.05. 
The overall error rate will be split between the endpoints: 
in the BIODOPT trial, the primary statistical tests have 
two steps. In step #1, we will assess the superiority claim 
of the BIODOPT intervention being better than control 
leading to reduced use of bDMARDs (p<0.05), while step 
#2 constitutes an equivalence claim, if and only if, step 
1 is statistically significant and the 95% CI around the 
between-group difference in disease is precise enough: 
95% CI: −0.5 to 0.5 disease activity units.
In addition, exploratory subanalysis will be performed 
to evaluate the effect of, for example, bDMARD drug.
data collection
Research personnel at each trial site will schedule partic-
ipant appointments and together with the coordinating 
investigator monitor participant retention to minimise 
the risk of missing data. If a participant misses a scheduled 
trial visit, he/she will be contacted by research personnel 
to schedule a new visit. Reasons for non-adherence and 
non-retention will be recorded.
Data are collected in an e-CRF in REDCap only accessible 
to research personnel by username and password. REDCap 
use data logging to create an audit trail thereby registering 
who is looking at, changing or entering data. Data quality 
will be promoted through the REDCap features real-time 
data entry validation (eg, for dates and range checks) and 
required data entry at each clinical visit. Thus, all trial-re-
lated information will be stored securely in REDCap with 
the exception of paper forms which will be stored securely 
at the trial sites. The BIODOPT trial complies with the 
Danish laws regarding patient confidentiality and is 
reported to the Danish Data Protection Agency. Data will 
be destroyed 15 years after the end of the trial.
The BIODOPT trial group will have access to the final 
data set. In addition, investigators will have access to the 
final data set from their own site.
Adverse events
All adverse events reported from baseline to the end 
of this trial will be registered and followed by the inves-
tigators to a satisfactory conclusion. An arthritis flare 
is not considered an AE. The investigators must report 
any serious adverse event or serious adverse reaction to 
the sponsor–investigator and coordinating investigator 
within 24 hours. A suspected unexpected serious adverse 
reaction will be reported to the medical products agency, 
the local ethics committee, the Danish Medicines Agency 
and the trial investigators within 7 days if judged to be life 
threatening otherwise within 15 days.
The section ‘adverse reactions’ in the product informa-
tion of the bDMARDs are used as referral documents for 
adverse events assessment.
data registration and monitoring
The BIODOPT trial is conducted in compliance with the 
protocol, Good Clinical Practice (GCP) and all other 
applicable regulatory requirements. Before start of partic-
ipant enrolment (17 May 2018), the trial was confirmed 
as registered at EudraCT (21 December 2017). The trial 
is monitored in accordance with the GCP monitoring 
plan by the local Danish GCP units at Aarhus, Aalborg 
and Odense University Hospitals to ensure that the trial is 
carried out in accordance with the protocol, IH-GCP and 
Danish laws.
EthICs And dIssEMInAtIon
Informed consent for the BIODOPT trial and for storage 
of blood in a biobank will be obtained from all patients 
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before study enrolment by the investigators. Patients 
can discontinue the trial prematurely without any conse-
quences for their future arthritis treatment; hence, they 
will receive standard arthritis care according to the 
national Danish guidelines.
Prior studies on this subject have found no consider-
able adverse events when tapering bDMARDs in patients 
with RA, PsA or axSpA in sustained clinical remission or 
LDA as a flare is treated successfully when escalating to 
standard dosage bDMARDs in most patients28 29 33 34 55–58; 
however, in a smaller proportion of patients switching to 
a different bDMARD can be necessary to gain remission/
LDA.33 55 58 59 When considering the well-known dose-de-
pendent risk of serious infection in arthritis patients 
treated with bDMARDs,60 it is expected that the interven-
tion group will have a smaller risk of adverse events incl. 
serious infections compared with the control group. In 
light of the above and the well-documented safety profile 
of the study drugs, a data monitoring committee will not 
be used during the conduct of this trial.
This trial is expected to contribute with new knowledge 
about dosage reduction of bDMARDs in patients with 
RA, PsA and axSpA in sustained remission/LDA; thereby, 
providing possible benefits for arthritis patients and the 
society. In light of the above, we consider it ethically justi-
fiable to conduct the trial.
Important protocol amendments require approval by 
the local Ethics Committee and the Danish Medicines 
Agency prior to implementation. The coordinating inves-
tigator will notify investigators at the trial sites.
All results of this trial both negative, inconclusive and 
positive will be reported; preferably, in English-language 
peer-reviewed medical journals as well as presented 
at international congresses. All persons designated as 
authors will qualify for authorship based on the ICMJE 
recommendations.
dIsCussIon
To our knowledge, the BIODOPT trial is the first prag-
matic, randomised controlled, equivalence study 
exploring a disease activity-guided tapering algorithm of 
bDMARDs in patients with RA, PsA or axSpA in sustained 
remission or LDA. The trial design with a coprimary 
endpoint of which 1A aims for superiority and 1B aims for 
equivalence was chosen, as we expect dosage reduction of 
bDMARDs by the BIODOPT algorithm to be superior in 
dosage reduction of bDMARDs but equivalent in main-
taining disease activity compared with usual care. The 
randomised controlled design with a comparator group 
receiving bDMARDs as usual care will provide statistical 
evidence evaluating dosage reduction of bDMARDs; 
thereby, contributing with important, new information.
The randomisation ratio was set to 2:1 (intervention 
group:control group) in order to obtain more data on the 
intervention group for subanalyses; however, it should be 
noted that the study is not powered to find a statistically 
significant difference between the disease groups nor 
the different bDMARDs but exploratory analyses will be 
made.
The BIODOPT trial is to our knowledge the first 
randomised, equivalence trial exploring a disease 
activity-guided tapering algorithm of seven different 
bDMARDs including biosimilars among patients with 
inflammatory arthritis. However, a limitation is that the 
trial personnel and the patients are not blinded to the 
intervention groups; thus, this could potentially lead to 
bias, for example, expectation and/or attribution bias 
which would affect interpretation of the trial results. 
After the primary endpoint assessment at 18 months, 
the patients will be followed up at 24 and 60 months 
from baseline; hence, data from these visits will give an 
important insight into the long-term effects of dosage 
reduction of bDMARDs.
As usual care practise in Denmark, the patient is an 
equal partner in his/her disease management; thus, the 
patient can remain at the current dosage of bDMARDs or 
even go back one step in the algorithm after agreement 
between the patient and physician.
Regarding the disease activity criteria for enrolment, 
DAS28crp was chosen for RA as a review of patients with 
RA from the Department of Rheumatology at Aalborg 
University Hospital showed that only 1 patient out of 31 
treated with bDMARDs who fulfilled DAS28crp remis-
sion but not CDAI remission had swollen joints, the 
remaining patients were not in CDAI remission because 
of a high patient VAS global disease activity. For patients 
with axSpA, ASDAS was selected over BASDAI as it is the 
recommended index by ASAS and EULAR.14 At present, 
there is to our knowledge no consensus regarding the 
preferred efficacy parameter for patients with PsA; 
however, DAPSA was chosen in this trial, as it is a stringent 
index that contains 66/68 joint count for swollen and 
tender joints and is one of the suggested efficacy scores by 
EULAR.10 Steroid treatment during the past year is listed 
as an exclusion criteria to ensure that the participants are 
in steroid-free remission/LDA at baseline.
In existing studies, it has been discussed if disease activity 
at baseline could be an effect modificator for successful 
tapering but the results were conflicting.61 However, 
in a recent systematic review by Tweehuysen et al it was 
concluded, that disease activity at baseline, that is, remis-
sion or LDA, was not an effect modificator for successful 
tapering of bDMARDs.61 Consequently, the inclusion 
criteria for disease activity for this trial was expanded after 
start of recruitment after approval of the relevant author-
ities; thus, patients with RA, PsA or axSpA in remission 
or LDA with no swollen joints will be enrolled. Inclusion 
of patients in both remission and LDA will improve the 
generalisability of the trial results.
In this trial, the ASAS definition of ASDAS worsening 
is used as a flare criteria for axSpA62 and the OMERACT 
recommended DAS28 flare criteria for patients with RA.63 
As no arthritis flare criteria exist for patients with PsA, the 
DAS28 flare criteria are also used for this patient group. 
However, we acknowledge that it would be desirably to 
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monitor patients with PsA using a PsA-validated flare 
criteria, for example, a DAPSA-based flare criteria as 
DAPSA is used as remission criteria for enrolment in this 
trial. Nevertheless, DAPSA will be calculated for patients 
with PsA for each trial visit for further subanalysis. In 
addition, PsA and axSpA essential outcomes as skin 
involvement, nail involvement, enthesitis and dactylitis 
will be monitored; hence, subanalysis will be performed 
and information about reason for dosage escalation of 
bDMARDs due to extra-articular manifestations will be 
collected , for example, psoriasis skin flare.
Tapering of bDMARDs is an important topic as an 
increasing number of arthritis patients reach sustained 
remission or LDA and continuation of standard dosage 
potentially can lead to overtreatment and unneces-
sary side effects such as infections. Dosage reduction by 
increasing the interval will result in less visits to the outpa-
tient clinic for IV infusions or longer interval between 
subcutaneous injections, which is expected to decrease 
the individual patient’s disease burden. In addition, 
bDMARDs are costly; thus, benefits for society (incl. costs) 
could be anticipated. In addition, we expect the results 
from the prognostic factor research to contribute with 
new, important information; hence, guiding and facili-
tating a shared decision-making regarding dosage reduc-
tion of bDMARDs for everyday clinical practice. Thus, 
the BIODOPT trial will contribute with new information, 
which can be used for guidance in the attempt to qualify 
the discussion on how to taper bDMARDs in patients with 
inflammatory arthritis in sustained remission or LDA. 
Therefore, we believe that the BIODOPT trial will lead to 
a significant change in the clinical management of these 
patients.
trial status
Recruitment started with first patient first visit on 
17 May 2018 and is expected to last until 1 September 
2019 or until the target population is reached. The co-or-
dination investigator will monitor enrolment rate during 
the inclusion period and send out a monthly newsletter 
with recruitment status to motivate investigators and 
research nurses.
The BIODOPT trial is currently running with first 
patient last visit scheduled for November 2019 and last 
patient last visit expected to be in February 2021.
Author affiliations
1Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
2Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg 
Hospital, Copenhagen, Denmark
3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
4Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
5Research Unit of Rheumatology, Department of Clinical Research, University of 
Southern Denmark, Odense University Hospital, Odense, Denmark
6Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
7Department of General Internal Medicine, University of Texas MD Anderson Cancer 
Center, Houston, Texas, USA
Acknowledgements The authors thank patient research partner Kathrine Hyldig 
Hansen for contributing to, and approving, the final protocol manuscript and 
final patient trial information. The authors would also like to thank data manager 
Johanne Hovgaard Winther for importing the concealed allocation sequences in 
REDCap and for technical support. 
Contributors LU, SK and AS conceived the trial hypothesis and LU, SK, AS, 
EMH and RC have designed the trial. SK is the trial sponsor-investigator and LU 
is the coordinating investigator. LU, SK, AS, EMH, RC and LD are responsible for 
implementation of the trial, analysis of the results and publication in scientific 
journals. LU, SK, AS, EMH and RC all contributed to refinement of the trial protocol 
and approved the final manuscript. LU wrote this protocol paper and SK, AS, LD, 
EMH, RC and MESA contributed with refinement and approved the final draft.
Funding This trial was initiated by the BIODOPT trial group; thus, no 
pharmaceutical companies or funding parties are involved in the design or conduct 
of the trial or analyses of the trial results. This work was supported by the Danish 
Regions (Regionernes Medicinpulje) grant number 16/2885, the Health Science 
Research Fund of the North Denmark Region grant number 2016-017615 and 
the Department of Rheumatology at Aalborg University Hospital. Musculoskeletal 
Statistics Unit at the Parker Institute is supported by a core grant from the Oak 
Foundation (OCAY-13-309). 
Competing interests LU has received speaker honoraria from Abbvie, Eli 
Lilly and Novartis (not related to the submitted work). SK has received speaker 
honoraria from Novartis and Eli Lilly (not related to the submitted work). AS has 
received speaker honoraria from MSD and Eli Lilly (not related to the submitted 
work). LD has received speaker honoraria from UCB, MSD, Eli Lilly and Janssen 
Pharmaceutica (not related to the submitted work).
Patient consent for publication Not required.
Ethics approval This trial is approved by the ethics committee of Northern 
Jutland, Denmark (N-20170073) and by the Danish Medicine Agency (2017091722) 
and the Danish Data Protection Agency (2017–194). The BIODOPT trial is conducted 
in accordance with the Helsinki Declaration. 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Singh J, Hossain A, Tanjong Ghogomu E, et al. Biologics or 
tofacitinib for rheumatoid arthritis in incomplete responders to 
methotrexate or other traditional disease modifying anti-rheumatic 
drugs: a systematic review and network meta-analysis. Cochrane 
Database Syst Rev 2016;5:CD012183.
 2. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors 
for ankylosing spondylitis. Cochrane Database Syst Rev 
2015;4:CD005468.
 3. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab 
pegol on signs and symptoms in patients with psoriatic arthritis: 
24-week results of a Phase 3 double-blind randomised placebo-
controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48–55.
 4. Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy 
of etanercept and its effects on objective signs of inflammation 
in early nonradiographic axial spondyloarthritis: a multicenter, 
randomized, double-blind, placebo-controlled trial. Arthritis 
Rheumatol 2014;66:2091–102.
 5. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab 
pegol on signs and symptoms of axial spondyloarthritis including 
ankylosing spondylitis: 24-week results of a double-blind randomised 
placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.
 6. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of 
infliximab plus naproxen versus naproxen alone in patients with early, 
active axial spondyloarthritis: results from the double-blind, placebo-
controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101–7.
 7. Sieper J, van der Heijde D, Dougados M, et al. A randomized, 
double-blind, placebo-controlled, sixteen-week study of 
subcutaneous golimumab in patients with active nonradiographic 
axial spondyloarthritis. Arthritis Rheumatol 2015;67:2702–12.
 8. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of 
adalimumab in patients with non-radiographic axial spondyloarthritis: 
results of a randomised placebo-controlled trial (ABILITY-1). Ann 
Rheum Dis 2013;72:815–22.









pen: first published as 10.1136/bm




10 Uhrenholt L, et al. BMJ Open 2019;9:e028517. doi:10.1136/bmjopen-2018-028517
Open access 
 9. Lemos LL, de Oliveira Costa J, Almeida AM, et al. Treatment of 
psoriatic arthritis with anti-TNF agents: a systematic review and 
meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 
2014;34:1345–60.
 10. Gossec L, Smolen JS, Ramiro S, et al. European League Against 
Rheumatism (EULAR) recommendations for the management of 
psoriatic arthritis with pharmacological therapies: 2015 update. Ann 
Rheum Dis 2016;75:499–510.
 11. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research 
and assessment of psoriasis and psoriatic arthritis 2015 treatment 
recommendations for psoriatic arthritis. Arthritis Rheumatol 
2016;68:1060–71.
 12. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations 
for the management of rheumatoid arthritis with synthetic and 
biological disease-modifying antirheumatic drugs: 2016 update. Ann 
Rheum Dis 2017;76:960–77.
 13. Singh JA, Saag KG, Sl BJ, et al. American College of Rheumatology 
guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 
2015;2016:1–26.
 14. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update 
of the ASAS-EULAR management recommendations for axial 
spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
 15. Ward MM, Deodhar A, Akl EA, et al. American College of 
Rheumatology/Spondylitis Association of America/Spondyloarthritis 
Research and Treatment Network 2015 Recommendations for the 
Treatment of Ankylosing Spondylitis and Nonradiographic Axial 
Spondyloarthritis. Arthritis Care Res 2016;68:151–66.
 16. Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing 
remission, low disease activity or radiographic progression in case 
of bDMARD discontinuation or tapering in rheumatoid arthritis: 
systematic analysis of the literature and meta-analysis. Ann Rheum 
Dis 2018;77:515–22.
 17. Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, et al. Flare rate 
in patients with rheumatoid arthritis in low disease activity or 
remission when tapering or stopping synthetic or biologic DMARD: a 
systematic review. J Rheumatol 2015;42:2012–22.
 18. Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, et al. 
Anti-TNF discontinuation and tapering strategies in patients with 
axial spondyloarthritis: a systematic literature review. Rheumatology 
2016;55:1188–94.
 19. Moverley A, Coates L, Marzo-Ortega H, et al. A feasibility study for 
a randomised controlled trial of treatment withdrawal in psoriatic 
arthritis (REmoval of treatment for patients in REmission in psoriatic 
ArThritis (RETREAT (F)). Clin Rheumatol 2015;34:1407–12.
 20. Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease 
recurrence after discontinuation of disease-modifying antirheumatic 
drug treatment in patients with psoriatic arthritis in remission. Ann 
Rheum Dis 2015;74:655–60.
 21. Covelli M, Scioscia C, Iannone F, et al. Repeated infusions of low-
dose infliximab plus methotrexate in psoriatic arthritis: immediate 
benefits are not maintained after discontinuation of infliximab. Clin 
Exp Rheumatol 2005;23:145–51.
 22. Gratacós J, Pontes C, Juanola X, et al. Non-inferiority of dose 
reduction versus standard dosing of TNF-inhibitors in axial 
spondyloarthritis. Arthritis Res Ther 2019;21:11.
 23. Verhoef LM, Tweehuysen L, Hulscher ME, et al. bDMARD dose 
reduction in rheumatoid arthritis: a narrative review with systematic 
literature search. Rheumatol Ther 2017;4:1–24.
 24. Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with 
biologic therapies: a systematic review and clinicians' perspective. 
Rheumatology 2017;56:1847–56.
 25. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and 
conventional DMARD therapy in rheumatoid arthritis: current 
evidence and future directions. Ann Rheum Dis 2016;75:1428–37.
 26. Lorenzin M, Ortolan A, de Hooge M, et al. Lengthening the time 
intervals between doses of biological agents in psoriatic arthritis 
patients: A single-center retrospective study. Int J Immunopathol 
Pharmacol 2015;28:479–87.
 27. de Stefano R, Frati E, de Quattro D, et al. Low doses of etanercept 
can be effective to maintain remission in psoriatic arthritis patients. J 
Clin Rheumatol 2018;24:127–31.
 28. Cantini F, Niccoli L, Cassarà E, et al. Sustained maintenance of 
clinical remission after adalimumab dose reduction in patients 
with early psoriatic arthritis: a long-term follow-up study. Biologics 
2012;6:201–6.
 29. Fong W, Holroyd C, Davidson B, et al. The effectiveness of a real 
life dose reduction strategy for tumour necrosis factor inhibitors 
in ankylosing spondylitis and psoriatic arthritis. Rheumatology 
2016;55:1837–42.
 30. van Herwaarden N, van der Maas A, Minten MJ, et al. Disease 
activity guided dose reduction and withdrawal of adalimumab 
or etanercept compared with usual care in rheumatoid arthritis: 
open label, randomised controlled, non-inferiority trial. BMJ 
2015;350:h1389.
 31. Bouman CA, van Herwaarden N, van den Hoogen FH, et al. Long-
term outcomes after disease activity-guided dose reduction of TNF 
inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a 
randomised controlled pragmatic non-inferiority strategy trial. Ann 
Rheum Dis 2017;76:1716–22.
 32. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing 
TNF-blocker injections for established rheumatoid arthritis in 
remission: results of the multicentre non-inferiority randomised open-
label controlled trial. Ann Rheum Dis 2016;75:59–67.
 33. Cantini F, Niccoli L, Cassarà E, et al. Duration of remission after 
halving of the etanercept dose in patients with ankylosing spondylitis: 
a randomized, prospective, long-term, follow-up study. Biologics 
2013;7:1–6.
 34. Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose 
reduction of TNF-α blocking agents in ankylosing spondylitis patients 
with stable low disease activity in daily clinical practice. Clin Exp 
Rheumatol 2015;33:174–80.
 35. Almirall M, Salman-Monte TC, Lisbona MP, et al. Dose reduction of 
biological treatment in patients with axial spondyloarthritis in clinical 
remission: Are there any differences between patients who relapsed 
and to those who remained in low disease activity? Rheumatol Int 
2015;35:1565–8.
 36. de Wit MP, Berlo SE, Aanerud GJ, et al. European league against 
rheumatism recommendations for the inclusion of patient 
representatives in scientific projects. Ann Rheum Dis 2011;70:722–6.
 37. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis 
classification criteria: an American College of Rheumatology/
European League Against Rheumatism Collaborative initiative. 
Arthritis Rheumatol 2010;2010:1580–8.
 38. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid 
arthritis. Arthritis Rheum 1988;31:315–24.
 39. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic 
criteria for ankylosing spondylitis. A proposal for modification of the 
New York criteria. Arthritis Rheum 1984;27:361–8.
 40. Rudwaleit M, van der Heijde D, Landewé R, et al. The development 
of Assessment of SpondyloArthritis international Society 
classification criteria for axial spondyloarthritis (part II): validation and 
final selection. Ann Rheum Dis 2009;68:777–83.
 41. Taylor W, Gladman D, Helliwell P, et al. Classification criteria 
for psoriatic arthritis: development of new criteria from a large 
international study. Arthritis Rheum 2006;54:2665–73.
 42. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 
1973;3:55–78.
 43. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid 
arthritis: agreement of the disease activity score (DAS28) with the 
ARA preliminary remission criteria. Rheumatology 2004;43:1252–5.
 44. Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic 
arthritis (PsA): defining remission and treatment success using the 
DAPSA score. Ann Rheum Dis 2016;75:811–8.
 45. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis 
Disease Activity Score (ASDAS): defining cut-off values for 
disease activity states and improvement scores. Ann Rheum Dis 
2011;70:47–53.
 46. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease 
activity scores that include twenty-eight-joint counts. Development 
and validation in a prospective longitudinal study of patients with 
rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
 47. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly 
discriminatory ASAS-endorsed disease activity score in patients with 
ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–8.
 48. Bjorner JB, Thunedborg K, Kristensen TS, et al. The Danish SF-36 
Health Survey: translation and preliminary validity studies. J Clin 
Epidemiol 1998;51:991–9.
 49. Cook JA, Julious SA, Sones W, et al. DELTA2 guidance on choosing 
the target difference and undertaking and reporting the sample size 
calculation for a randomised controlled trial. BMJ 2018;363:k3750.
 50. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting 
and transparency of rheumatology research: a guide to reporting 
guidelines. Arthritis Res Ther 2013;15:109.
 51. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation 
and elaboration: updated guidelines for reporting parallel group 
randomised trials. BMJ 2010;340:c869.
 52. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority 
and equivalence randomized trials: extension of the CONSORT 2010 
statement. JAMA 2012;308:2594–604.
 53. Dossing A, Tarp S, Furst DE, et al. Interpreting trial results following 
use of different intention-to-treat approaches for preventing 









pen: first published as 10.1136/bm




11Uhrenholt L, et al. BMJ Open 2019;9:e028517. doi:10.1136/bmjopen-2018-028517
Open access
attrition bias: a meta-epidemiological study protocol. BMJ Open 
2014;4:e005297.
 54. Dmitrienko A, D'Agostino RB. Multiplicity considerations in clinical 
trials. N Engl J Med 2018;378:2115–22.
 55. Raffeiner B, Botsios C, Ometto F, et al. Effects of half dose 
etanercept (25 mg once a week) on clinical remission and 
radiographic progression in patients with rheumatoid arthritis in 
clinical remission achieved with standard dose. Clin Exp Rheumatol 
2015;33:63–8.
 56. van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, et al. Full dose, 
reduced dose or discontinuation of etanercept in rheumatoid arthritis. 
Ann Rheum Dis 2016;75:52–8.
 57. Maneiro JR, Perez-Pampin E, Salgado E, et al. Observational study 
of optimization of biologic therapies in rheumatoid arthritis: a single-
centre experience. Rheumatol Int 2014;34:1059–63.
 58. Rodriguez-Rodriguez L, Leon L, Lamas JR, et al. Dose down-titration 
of biological DMARDs in patients with rheumatoid arthritis over time 
and in daily clinical practice. Clin Exp Rheumatol 2016;34:872–9.
 59. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration 
and discontinuation of infliximab in rheumatoid arthritis patients with 
stable low disease activity and stable treatment: an observational 
cohort study. Ann Rheum Dis 2012;71:1849–54.
 60. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious 
infection in biological treatment of patients with rheumatoid 
arthritis: a systematic review and meta-analysis. Lancet 
2015;386:258–65.
 61. Tweehuysen L, van den Ende CH, Beeren FM, et al. Little evidence 
for usefulness of biomarkers for predicting successful dose reduction 
or discontinuation of a biologic agent in rheumatoid arthritis: a 
systematic review. Arthritis Rheumatol 2017;69:301–8.
 62. Molto A, Gossec L, Meghnathi B, et al. An Assessment in 
SpondyloArthritis International Society (ASAS)-endorsed definition 
of clinically important worsening in axial spondyloarthritis based on 
ASDAS. Ann Rheum Dis 2018;77:124–7.
 63. van der Maas A, Lie E, Christensen R, et al. Construct and criterion 
validity of several proposed DAS28-based rheumatoid arthritis 
flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 
2013;72:1800–5.
 64. Felson DT, Anderson JJ, Boers M, et al. The American College of 
Rheumatology preliminary core set of disease activity measures 
for rheumatoid arthritis clinical trials. The Committee on Outcome 
Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 
1993;36:729–40.
 65. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue 
in rheumatic disease. J Rheumatol 1996;23:1407–17.
 66. Thorsen H, Hansen TM, McKenna SP, et al. Adaptation into Danish 
of the Stanford Health Assessment Questionnaire (HAQ) and 
the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J 
Rheumatol 2001;30:103–9.
 67. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing 
Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
 68. Calin A, Garrett S, Whitelock H, et al. A new approach to defining 
functional ability in ankylosing spondylitis: the development of 
the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 
1994;21:2281–5.
 69. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal 
mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. 
J Rheumatol 1994;21:1694–8.
 70. Maksymowych WP, Mallon C, Morrow S, et al. Development and 
validation of the Spondyloarthritis Research Consortium of Canada 
(SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948–53.
 71. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a 
new retinoid. Dermatologica 1978;157:238–44.
 72. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis 
Severity Index: validation of an instrument to assess psoriatic 
nail involvement in patients with psoriatic arthritis. J Rheumatol 
2007;34:123–9.









pen: first published as 10.1136/bm
jopen-2018-028517 on 9 July 2019. D
ow
nloaded from
 
